Health Catalyst appoints Simeon Kohl as CEO with 2.75M share inducement award
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-15. Check what remains unresolved below before relying on it.
Does this insider transaction strengthen the investment case?
Executive leadership change accompanied by a 2.75M share equity inducement restructures governance incentives for HCAT enterprise healthcare data analytics.
| Question | What the evidence establishes |
|---|---|
| Did the insider change their personal exposure? | Reported factHealth Catalyst, Inc. appointed Simeon Kohl as Chief Executive Officer and President effective September 14, 2026. |
| On what terms? | Reported factKohl received an employment inducement grant of 2,747,385 restricted stock units under Nasdaq Listing Rule 5635(c)(4). |
| Is this unusual buying or selling activity? | UnknownPrior insider transactions for this company are not in the public record here. |
| Does it establish improving business performance? | UnknownNot by itself. A transaction reflects one person's decision; operating results are needed to test it. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for HCAT yet — this is the next research task. |
| What would change the assessment? | UnknownHealth Catalyst strategy presentation date — First public remarks or operational guidance update from CEO Simeon Kohl. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Health Catalyst, Inc. appointed Simeon Kohl as Chief Executive Officer and President effective September 14, 2026.
- · Kohl received an employment inducement grant of 2,747,385 restricted stock units under Nasdaq Listing Rule 5635(c)(4).
- · The equity award vests over approximately two years, with the first tranche of 915,975 RSUs vesting after one year.
Public research record
Research framework · page evidenceCompleted event assessment
leadership transition and future share dilution from 2.75M RSU grant
| Type | Claim | Scope |
|---|---|---|
| Assumption | Health Catalyst, Inc. appointed Simeon Kohl as Chief Executive Officer and President effective September 14, 2026. | 2026-09-15 |
| Interpretation | leadership transition and future share dilution from 2.75M RSU grant | HCAT |
Countercase, invalidators, and sources
New leadership accelerates enterprise software subscription wins and operational margin turnaround.
- · Health Catalyst strategy presentation date — First public remarks or operational guidance update from CEO Simeon Kohl.
- Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) · 2026-09-14
What remains unresolved
- Base path
- HCAT shares trade flat as the market assesses strategic priorities under incoming management.
- Adverse path
- Management transition delays contract renewals and creates friction in core hospital client accounts.
- Supportive path
- New leadership accelerates enterprise software subscription wins and operational margin turnaround.
- · Health Catalyst strategy presentation date — First public remarks or operational guidance update from CEO Simeon Kohl.this week
Evidence
- Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)2026-09-14
“Health Catalyst, Inc. announced the appointment of Simeon Kohl as Chief Executive Officer and President effective September 14, 2026. As part of his employment inducement, Kohl was granted 2,747,385 restricted stock units”
Supports: Health Catalyst appointed Simeon Kohl CEO with 2,747,385 RSUs under Nasdaq Rule 5635(c)(4).